|By PR Newswire||
|March 14, 2014 08:00 AM EDT||
NEW YORK, March 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Medtronic, Inc. (NYSE: MDT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Illumina, Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Celgene Corporation Analyst Notes
On its events page, Celgene Corporation (Celgene) posted the schedule of two upcoming conferences that the Company will participate in during the ongoing month. Celgene will be a part of the American Academy of Dermatology (AAD) Annual Meeting at the Colorado Convention Center in Denver, CO, which will be held from March 21 to March 25, 2014. The Company will also take part in the European Lung Cancer Conference (ELCC) at Palexpo in Geneva, Switzerland, which will take place from March 26 to March 29, 2014. The full analyst notes on Celgene Corporation are available to download free of charge at:
Medtronic, Inc. Analyst Notes
On March 10, 2014, Medtronic, Inc. (Medtronic) announced that the applications for runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team are now open. According to Medtronic, up to 25 runners will be chosen to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 Mile. The Company informed that the 2014 Medtronic Twin Cities Marathon weekend will take place from October 3 to October 5, 2014, and that the deadline for application is April 25, 2014. The full analyst notes on Medtronic, Inc. are available to download free of charge at:
Alexion Pharmaceuticals, Inc. Analyst Notes
On March 10, 2014, Alexion Pharmaceuticals, Inc. (Alexion) revised its previously announced 2014 financial guidance for net product sales and non-GAAP earnings per share (EPS). Alexion stated that its 2014 net revenue guidance has been increased to a range of $2,150 to $2,170 million from its prior guidance range of $2,000 to $2,020 million. The Company said that it will record increased revenue in 2014 related to an agreement that brings to conclusion discussions with the French government and which positively impacts prospective reimbursement of Soliris. Non-GAAP EPS is now expected in the range of $4.37 to $4.47, up from the Company's previous expectation of $3.70 to $3.80. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:
Quest Diagnostics Inc. Analyst Notes
On March 11, 2014, Quest Diagnostics Inc. (Quest Diagnostics) announced that it has entered into an agreement to acquire Summit Health - a leading provider of on-site prevention and wellness programs mainly for employees. Steve Rusckowski, President and CEO, Quest Diagnostics, stated "This acquisition supports Quest Diagnostics' five-point strategy, which includes restoring growth and driving disciplined capital deployment. One of our capital deployment objectives is to grow one to two percent a year through strategically aligned, accretive acquisitions." Terms of the transaction were not disclosed. The full analyst notes on Quest Diagnostics Inc. are available to download free of charge at:
Illumina, Inc. Analyst Notes
On March 10, 2014, Illumina, Inc. (Illumina) and WuXi PharmaTech (Cayman) Inc. announced that the Wuxi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. The Company informed that HiSeq X Ten is the world's first platform to deliver full coverage human genomes. Illumina stated that the purchase will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing, putting the world's most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. "This investment in cutting-edge gene sequencing technology significantly strengthens WuXi's broad, integrated platform of R&D services," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It advances our mission of enabling anyone and any company to use our R&D platform to discover and develop innovative medicines to benefit the world's patients." The full analyst notes on Illumina, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review